Compound ID | 3060

Update compound information

Ceftibuten + VNRX-7145

Class: Beta-lactam + beta-lactamase inhibitor

Agent Type: Semisynthetic; Small molecule; Direct acting; Indirect acting; Antibiotic adjuvant;
Spectrum of activity: Gram-negative
Mechanism of action: Cell wall synthesis inhibitor
Target Pathogen: Active against Enterobacteriaceae
Combined with other compounds: Yes
Description: Semisynthetic compound; third generation cephalosporin and cyclic boronate beta-lactamase inhibitor
Institute where first reported: VentoRx Pharmaceuticals
Year first mentioned: 2022
Highest development stage: Phase 1 (NCT04243863)
Development status: Active (as of 2024)
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/5282242
Citation: https://journals.asm.org/doi/full/10.1128/aac.01304-21?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org

AntibioticDB is supported by GARDP.

If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.